Relation of myeloperoxidase promoter polymorphism and long-term hormone replacement therapy to oxidized low-density lipoprotein autoantibodies in postmenopausal women

Objective. The myeloperoxidase enzyme (MPO) is a potent precursor of low-density lipoprotein (LDL) oxidation in atherosclerotic lesions. The MPO gene has a promoter polymorphism, 463G A, which leads to high (GG) and low-expression (AG, AA) genotypes. Hormone replacement therapy (HRT) is known to aff...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scandinavian journal of clinical and laboratory investigation 2006, Vol.66 (5), p.371-384
Hauptverfasser:	Mäkelä, R., Dastidar, P., Jokela, H., Jaakkola, O., Saarela, M., Punnonen, R., Lehtimäki, T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Apolipoproteins - blood Atherosclerosis Atherosclerosis - genetics Atherosclerosis - immunology Autoantibodies - immunology Enzyme-Linked Immunosorbent Assay Female Genotype Hormone Replacement Therapy Humans LDL oxidation Lipoproteins, LDL - immunology Middle Aged myeloperoxidase Peroxidase - genetics Polymorphism, Genetic - genetics Postmenopause - drug effects Postmenopause - genetics Postmenopause - immunology Promoter Regions, Genetic - genetics Retrospective Studies Risk Factors Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!